Suppr超能文献

儿童肺动脉高压与前列环素治疗:长期血液动力学。

Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.

机构信息

Division of Pediatric Cardiology, Department of Pediatrics, Stanford University, Palo Alto, California 94304, USA.

出版信息

J Heart Lung Transplant. 2013 May;32(5):546-52. doi: 10.1016/j.healun.2013.01.1055. Epub 2013 Feb 28.

Abstract

BACKGROUND

Pediatric patients with severe pulmonary arterial hypertension (PAH) are treated with intravenous epoprostenol or intravenous or subcutaneous treprostinil. Little is known about longitudinal hemodynamics and outcomes of epoprostenol, treprostinil, and transitions from epoprostenol to treprostinil.

METHODS

This was retrospective study of 77 pediatric patients (47 idiopathic PAH, 24 congenital heart disease-PAH) receiving epoprostenol or treprostinil from 1992 to 2010 at 2 centers. Outcomes were defined as living vs dead/transplant.

RESULTS

Mean age at baseline was 7.7 ± 5.2 years, with follow-up of 4.3 ± 3.4 years. Thirty-seven patients were treated with epoprostenol, 20 with treprostinil, and 20 were transitioned from epoprostenol to treprostinil. Mean pulmonary-to-systemic vascular resistance ratio (Rp/Rs) for epoprostenol was 1.0 ± 0.4, 0.8 ± 0.4, 0.8 ± 0.4, 1.0 ± 0.4, and 1.2 ± 0.4, respectively, at baseline, 1, 2, 3, and 4 years. For treprostinil, Rp/Rs was 0.9 ± 0.3, 0.7 ± 0.3, 0.5 ± 0.2, (p < 0.01 vs baseline), and 1.1 ± 0.2, respectively, at baseline, 1, 2, and 3 to 4 years, respectively. There were similar changes in mean pulmonary artery pressure and pulmonary vascular resistance index. The Rp/Rs 1 year after epoprostenol to treprostinil transition increased from 0.6 to 0.8 (n = 7). Changes not statistically significant unless noted. Eight patients died or received a transplant within 2 years of baseline; compared with the rest of the cohort, mean baseline Rp/Rs, right atrial pressure, and pulmonary vascular resistance index were significantly worse in this group. Thirty-nine patients remain on prostanoids, 17 are off, 16 died, and 5 received heart-lung transplant. Kaplan-Meier 5-year transplant-free survival was 70% (95% confidence interval, 56%-80%).

CONCLUSION

There was improvement in Rp/Rs on both therapies at 1 to 2 years that was not sustained. The 5-year transplant-free survival was better than in similar adult studies.

摘要

背景

患有严重肺动脉高压(PAH)的儿科患者接受静脉内依前列醇或静脉内或皮下曲前列尼尔治疗。对于依前列醇、曲前列尼尔以及从依前列醇转换为曲前列尼尔的纵向血液动力学和结局,知之甚少。

方法

这是一项回顾性研究,纳入了 1992 年至 2010 年在两个中心接受依前列醇或曲前列尼尔治疗的 77 名儿科患者(47 名特发性 PAH,24 名先天性心脏病-PAH)。结局定义为存活与死亡/移植。

结果

基线时的平均年龄为 7.7 ± 5.2 岁,随访时间为 4.3 ± 3.4 年。37 名患者接受依前列醇治疗,20 名患者接受曲前列尼尔治疗,20 名患者从依前列醇转换为曲前列尼尔。依前列醇的肺-体循环血管阻力比(Rp/Rs)分别为基线时的 1.0 ± 0.4、1.0 ± 0.4、1.0 ± 0.4、1.0 ± 0.4 和 1.2 ± 0.4,1 年、2 年、3 年和 4 年。曲前列尼尔的 Rp/Rs 分别为基线时的 0.9 ± 0.3、0.7 ± 0.3、0.5 ± 0.2、(p < 0.01 与基线相比)和 1.1 ± 0.2,1 年、2 年和 3 至 4 年。平均肺动脉压和肺血管阻力指数均有类似的变化。依前列醇转换为曲前列尼尔后 1 年 Rp/Rs 从 0.6 增加到 0.8(n = 7)。除非另有说明,否则变化不具有统计学意义。8 名患者在基线后 2 年内死亡或接受了移植;与队列中的其余患者相比,该组的平均基线 Rp/Rs、右心房压和肺血管阻力指数明显更差。39 名患者仍在使用前列环素,17 名已停药,16 名死亡,5 名接受心肺移植。Kaplan-Meier 5 年无移植生存为 70%(95%置信区间,56%-80%)。

结论

两种治疗方法在 1 至 2 年内 Rp/Rs 均有改善,但未持续。5 年无移植生存率优于类似的成人研究。

相似文献

1
Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.
J Heart Lung Transplant. 2013 May;32(5):546-52. doi: 10.1016/j.healun.2013.01.1055. Epub 2013 Feb 28.
2
One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
J Heart Lung Transplant. 2013 Sep;32(9):889-96. doi: 10.1016/j.healun.2013.06.008.
4
Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.
J Heart Lung Transplant. 2017 Feb;36(2):193-201. doi: 10.1016/j.healun.2016.06.019. Epub 2016 Jun 24.
5
Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.
Am J Cardiol. 2012 Nov 15;110(10):1546-50. doi: 10.1016/j.amjcard.2012.07.012. Epub 2012 Jul 30.
7
Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
Am J Respir Crit Care Med. 2005 Dec 15;172(12):1586-9. doi: 10.1164/rccm.200505-766OC. Epub 2005 Sep 8.
9
Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension.
Int J Cardiol. 2018 Aug 1;264:153-157. doi: 10.1016/j.ijcard.2018.03.067. Epub 2018 Mar 15.
10
Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension.
Pulm Pharmacol Ther. 2011 Aug;24(4):421-5. doi: 10.1016/j.pupt.2011.01.002. Epub 2011 Jan 18.

引用本文的文献

4
Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients.
Pulm Circ. 2023 Apr 1;13(2):e12224. doi: 10.1002/pul2.12224. eCollection 2023 Apr.
5
Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension.
Pulm Circ. 2022 Oct 1;12(4):e12159. doi: 10.1002/pul2.12159. eCollection 2022 Oct.
6
Critical Care Management of Decompensated Right Heart Failure in Pulmonary Arterial Hypertension Patients - An Ongoing Approach.
J Crit Care Med (Targu Mures). 2021 Aug 5;7(3):170-183. doi: 10.2478/jccm-2021-0020. eCollection 2021 Jul.
9
Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment.
Compr Physiol. 2021 Jun 30;11(3):2135-2190. doi: 10.1002/cphy.c200023.
10
Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine.
Ann Am Thorac Soc. 2022 Feb;19(2):227-237. doi: 10.1513/AnnalsATS.202012-1563OC.

本文引用的文献

1
Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension.
J Pediatr. 2011 Apr;158(4):584-8. doi: 10.1016/j.jpeds.2010.09.025. Epub 2010 Oct 30.
2
Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies.
Am J Cardiol. 2010 Jul 1;106(1):117-24. doi: 10.1016/j.amjcard.2010.02.023.
5
Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease.
J Pediatr. 2009 Mar;154(3):379-84, 384.e1-2. doi: 10.1016/j.jpeds.2008.09.021. Epub 2008 Oct 31.
6
Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension.
J Am Coll Cardiol. 2008 Jan 15;51(2):161-9. doi: 10.1016/j.jacc.2007.09.031.
7
Epoprostenol treatment in children with severe pulmonary hypertension.
Heart. 2007 Jun;93(6):739-43. doi: 10.1136/hrt.2006.096412. Epub 2006 Oct 25.
8
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.
Eur Respir J. 2006 Dec;28(6):1195-203. doi: 10.1183/09031936.06.00044406. Epub 2006 Aug 9.
9
Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
Am J Respir Crit Care Med. 2005 Dec 15;172(12):1586-9. doi: 10.1164/rccm.200505-766OC. Epub 2005 Sep 8.
10
Effects of long-term bosentan in children with pulmonary arterial hypertension.
J Am Coll Cardiol. 2005 Aug 16;46(4):697-704. doi: 10.1016/j.jacc.2005.01.066.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验